🚀 VC round data is live in beta, check it out!
DaShenLin Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for DaShenLin Pharmaceutical and similar public comparables like Sundrug, Fragua, Nahdi Medical, COSMOS Pharmaceutical and more.
DaShenLin Pharmaceutical Overview
About DaShenLin Pharmaceutical
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
Founded
1999
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$3B
DaShenLin Pharmaceutical Financials
DaShenLin Pharmaceutical reported last 12-month revenue of $4B and EBITDA of $442M.
In the same LTM period, DaShenLin Pharmaceutical generated $1B in gross profit, $442M in EBITDA, and $184M in net income.
Revenue (LTM)
DaShenLin Pharmaceutical P&L
In the most recent fiscal year, DaShenLin Pharmaceutical reported revenue of $4B and EBITDA of $449M.
DaShenLin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4B | XXX | $4B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $442M | XXX | $449M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $184M | XXX | $133M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 4% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
DaShenLin Pharmaceutical Stock Performance
DaShenLin Pharmaceutical has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
DaShenLin Pharmaceutical's stock price is $2.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 1.0% | XXX | XXX | XXX | $0.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaShenLin Pharmaceutical Valuation Multiples
DaShenLin Pharmaceutical trades at 0.8x EV/Revenue multiple, and 7.0x EV/EBITDA.
EV / Revenue (LTM)
DaShenLin Pharmaceutical Financial Valuation Multiples
As of March 19, 2026, DaShenLin Pharmaceutical has market cap of $3B and EV of $3B.
Equity research analysts estimate DaShenLin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DaShenLin Pharmaceutical has a P/E ratio of 17.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 7.0x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 11.4x | XXX | 13.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| P/E | 17.3x | XXX | 23.9x | XXX | XXX | XXX |
| EV/FCF | 34.3x | XXX | 13.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DaShenLin Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
DaShenLin Pharmaceutical Margins & Growth Rates
DaShenLin Pharmaceutical's revenue in the last 12 month grew by 10%.
DaShenLin Pharmaceutical's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DaShenLin Pharmaceutical's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
DaShenLin Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | (5%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
DaShenLin Pharmaceutical Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sundrug | XXX | XXX | XXX | XXX | XXX | XXX |
| Fragua | XXX | XXX | XXX | XXX | XXX | XXX |
| Nahdi Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| COSMOS Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Ebos Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DaShenLin Pharmaceutical M&A Activity
DaShenLin Pharmaceutical acquired XXX companies to date.
Last acquisition by DaShenLin Pharmaceutical was on XXXXXXXX, XXXXX. DaShenLin Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by DaShenLin Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDaShenLin Pharmaceutical Investment Activity
DaShenLin Pharmaceutical invested in XXX companies to date.
DaShenLin Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. DaShenLin Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by DaShenLin Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DaShenLin Pharmaceutical
| When was DaShenLin Pharmaceutical founded? | DaShenLin Pharmaceutical was founded in 1999. |
| Where is DaShenLin Pharmaceutical headquartered? | DaShenLin Pharmaceutical is headquartered in China. |
| Is DaShenLin Pharmaceutical publicly listed? | Yes, DaShenLin Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical trades under 603233 ticker. |
| When did DaShenLin Pharmaceutical go public? | DaShenLin Pharmaceutical went public in 2017. |
| Who are competitors of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical main competitors are Sundrug, Fragua, Nahdi Medical, COSMOS Pharmaceutical. |
| What is the current market cap of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's current market cap is $3B. |
| What is the current revenue of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months revenue is $4B. |
| What is the current revenue growth of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of DaShenLin Pharmaceutical? | Current revenue multiple of DaShenLin Pharmaceutical is 0.8x. |
| Is DaShenLin Pharmaceutical profitable? | Yes, DaShenLin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months EBITDA is $442M. |
| What is DaShenLin Pharmaceutical's EBITDA margin? | DaShenLin Pharmaceutical's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of DaShenLin Pharmaceutical? | Current EBITDA multiple of DaShenLin Pharmaceutical is 7.0x. |
| What is the current FCF of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months FCF is $90M. |
| What is DaShenLin Pharmaceutical's FCF margin? | DaShenLin Pharmaceutical's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of DaShenLin Pharmaceutical? | Current FCF multiple of DaShenLin Pharmaceutical is 34.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.